Obagi Medical, a prominent player in physician-dispensed skincare and aesthetic solutions and a part of Waldencast plc (NASDAQ: WALD), has presented new clinical findings on its hyaluronic acid injectables at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. This event, held from November 13 to 16, 2025, in Chicago, Illinois, showcased significant advancements in midface augmentation techniques and their impact on the appearance of nasolabial folds.
During the conference, a pivotal study comparing two hyaluronic acid fillers for midface augmentation was highlighted. This research, which demonstrated the efficacy of Obagi Hyaluronic Acid, was recognized as one of the top ten abstracts presented, with Dr. Sue Ellen Cox leading the discussion. The findings underscore the potential of these injectables to enhance facial aesthetics effectively.
The study compared the performance of Obagi’s products against other leading fillers, focusing on patient satisfaction and visible results in reducing the prominence of nasolabial folds. Participants reported noticeable improvements, which could influence future treatment protocols across the industry.
The recognition at the ASDS meeting adds to Obagi Medical’s reputation as an innovator in the skincare sector. As the demand for non-surgical aesthetic procedures continues to rise, the company aims to position itself at the forefront of this growth, providing healthcare professionals with proven solutions that meet the evolving needs of their patients.
In addition to the focus on hyaluronic acid injectables, Obagi Medical continues to expand its product offerings, ensuring they align with current market trends and consumer preferences. The company is dedicated to rigorous research and development, striving to maintain high standards in efficacy and safety.
Overall, the data presented at the ASDS Annual Meeting highlights Obagi Medical’s commitment to advancing aesthetic medicine. As the landscape of skincare evolves, the insights gained from this study will likely have a lasting impact on treatment approaches and patient outcomes in the field of dermatology.
